These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27964905)

  • 21. Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology.
    Potters L; Calguaru E; Thornton KB; Jackson T; Huang D
    Brachytherapy; 2003; 2(3):172-80. PubMed ID: 15062140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
    Rosenthal SA; Bittner NH; Beyer DC; Demanes DJ; Goldsmith BJ; Horwitz EM; Ibbott GS; Lee WR; Nag S; Suh WW; Potters L; ;
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):335-41. PubMed ID: 21106306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64.
    Yu Y; Anderson LL; Li Z; Mellenberg DE; Nath R; Schell MC; Waterman FM; Wu A; Blasko JC
    Med Phys; 1999 Oct; 26(10):2054-76. PubMed ID: 10535622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance.
    Eberhardt SC; Carter S; Casalino DD; Merrick G; Frank SJ; Gottschalk AR; Leyendecker JR; Nguyen PL; Oto A; Porter C; Remer EM; Rosenthal SA
    J Am Coll Radiol; 2013 Feb; 10(2):83-92. PubMed ID: 23374687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
    Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
    Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar Cancer.
    Jolly S; Soni P; Gaffney DK; Biagioli M; Elshaikh MA; Jhingran A; Kidd E; Lee LJ; Li L; Moore DH; Rao GG; Wahl AO; Williams NL; Yashar CM; Small W
    Oncology (Williston Park); 2015 Nov; 29(11):867-72, 874-5. PubMed ID: 26568534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of intraoperative ultrasound with postimplant computed tomography--dosimetric values at Day 1 and Day 30 after prostate brachytherapy.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T; Nagata H; Kosugi M; Shigematsu N; Kubo A
    Brachytherapy; 2007; 6(4):246-53. PubMed ID: 17959425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry.
    Lee J; Mian OY; Le Y; Bae HJ; Burdette EC; DeWeese TL; Prince JL; Song DY
    Radiother Oncol; 2017 Jul; 124(1):61-67. PubMed ID: 28647400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACR Appropriateness Criteria® non-spine bone metastases.
    ; Lutz ST; Lo SS; Chang EL; Galanopoulos N; Howell DD; Kim EY; Konski AA; Pandit-Taskar ND; Ryu S; Silverman LN; Van Poznak C; Weber KL
    J Palliat Med; 2012 May; 15(5):521-6. PubMed ID: 22536988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.
    Jabbari S; Hsu IC; Kawakami J; Weinberg VK; Speight JL; Gottschalk AR; Roach M; Shinohara K
    Brachytherapy; 2009; 8(4):339-44. PubMed ID: 19428310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
    Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
    Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ACR Appropriateness Criteria® posttreatment follow-up of prostate cancer.
    Casalino DD; Remer EM; Arellano RS; Bishoff JT; Coursey CA; Dighe M; Eggli DF; Fulgham P; Israel GM; Lazarus E; Leyendecker JR; Nikolaidis P; Papanicolaou N; Prasad S; Ramchandani P; Sheth S; Vikram R
    J Am Coll Radiol; 2011 Dec; 8(12):863-71. PubMed ID: 22137005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy].
    Herein A; Ágoston P; Szabó Z; Jorgo K; Markgruber B; Pesznyák C; Polgár C; Major T
    Magy Onkol; 2015 Jun; 59(2):148-53. PubMed ID: 26035163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
    Lawton CA; DeSilvio M; Lee WR; Gomella L; Grignon D; Gillin M; Morton G; Pisansky T; Sandler H
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):39-47. PubMed ID: 17084551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II prospective trial of cancer-specific imaging using ultrasound spectrum analysis tissue-type imaging to guide dose-painting prostate brachytherapy.
    Ennis RD; Quinn SA; Trichter F; Ryemon S; Jain A; Saigal K; Chandrashekhar S; Romas NA; Feleppa EJ
    Brachytherapy; 2015; 14(6):801-8. PubMed ID: 26235201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Permanent prostate brachytherapy: lessons learned, lessons to learn.
    Potters L
    Oncology (Williston Park); 2000 Jul; 14(7):981-91; discussion 991-2, 997-9. PubMed ID: 10929587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the feasibility of using transrectal ultrasound for postimplant dosimetry in low-dose-rate prostate brachytherapy.
    Davies RS; Perrett T; Powell J; Barber J; Tanguay J; Button M; Cochlin D; Smith C; Lester JF
    Med Dosim; 2016 Winter; 41(4):290-295. PubMed ID: 27623391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures.
    Lee DJ; Barocas DA; Zhao Z; Huang LC; Koyama T; Resnick MJ; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
    Pract Radiat Oncol; 2018; 8(5):307-316. PubMed ID: 30177030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.